Advanced Bio-Surfaces medial knee implant:
This article was originally published in Clinica
The US FDA has given Advanced Bio-Surfaces (ABS) 510(k) clearance to sell its first orthopaedic product, a minimally-invasive medial knee implant for helping to replace some of the cartilage functions lost due to osteoarthritis. The OrthoGlide device, which was also recently approved in Europe, is made of cobalt-chrome and provides for positional stability without the use of rigid fixation methods. In addition, it features a specially contoured geometry that provides an open glide path, allowing for the unconstrained motion of the femoral condyle. Jeff Felt, the Minneapolis, Minnesota firm's chairman and CEO, said that other invasive treatments usually require extensive tissue and bone removal. "From a technology standpoint this has been an under-served area of orthopaedics. The introduction of OrthoGlide represents an excellent opportunity for ABS to capture a significant section of this expanding market."